$BPMC vs. $LOXO RETi showdown in MTC #ATAThyroid2018 $LOXO 56%(15/27) cORR in RET-mutant MTC 78%(7/9) cORR in RET fusion-positive thyroid cancer https://ir.loxooncology.com/docs/events/ATA_2018_LOXO-292_Final.pdf … $BPMC 49%(17/35) ORR in RET-alter

10:14 EDT 6 Oct 2018 | Andy Biotech

$BPMC vs. $LOXO RETi showdown in MTC #ATAThyroid2018 $LOXO 56%(15/27) cORR in RET-mutant MTC 78%(7/9) cORR in RET fusion-positive thyroid cancer https://ir.loxooncology.com/docs/events/ATA_2018_LOXO-292_Final.pdf … $BPMC 49%(17/35) ORR in RET-altered thyroid cancer http://www.blueprintmedicines.com/wp-content/uploads/2018/10/ATA_BLU667_Oral-Presentation-06Oct2018-Final.pdf … Pretty amazing waterfall plots! pic.twitter.com/vH3bShEKlJ

More From BioPortfolio on "$BPMC vs. $LOXO RETi showdown in MTC #ATAThyroid2018 $LOXO 56%(15/27) cORR in RET-mutant MTC 78%(7/9) cORR in RET fusion-positive thyroid cancer https://ir.loxooncology.com/docs/events/ATA_2018_LOXO-292_Final.pdf … $BPMC 49%(17/35) ORR in RET-alter"